N- (cyclopropylmethyl)- 7- (2,6- dimethoxy- 4- (methoxymethyl)phenyl)- 2- ethyl- N- ((tetrahydro- 2H- pyran- 4- yl)methyl)pyrazolo(1,5- a)pyridin- 3- amine

a CRF1 receptor antagonist; structure in first source

Also Known As:

E2508; N-(cyclopropylmethyl)-7-(2,6-dimethoxy-4-(methoxymethyl)phenyl)-2-ethyl-N-((tetrahydro-2H-pyran-4-yl)methyl)pyrazolo(1,5-a)pyridin-3-amine 4-methylbenzenesulfonate

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - N-(cyclopropylmethyl)-7-(2,6-dimethoxy-4-(methoxymethyl)phenyl)-2-ethyl-N-((tetrahydro-2H-pyran-4-yl)methyl)pyrazolo(1,5-a)pyridin-3-amine: 1
  - Pyridines: 88
    - N-(cyclopropylmethyl)-7-(2,6-dimethoxy-4-(methoxymethyl)phenyl)-2-ethyl-N-((tetrahydro-2H-pyran-4-yl)methyl)pyrazolo(1,5-a)pyridin-3-amine: 1

Experts

1.	Furuya, Yoshiaki: 1 article (01/2017)
2.	Hirakawa, Tetsuya: 1 article (01/2017)
3.	Ino, Mitsuhiro: 1 article (01/2017)
4.	Shibata, Hisashi: 1 article (01/2017)
5.	Shikata, Kodo: 1 article (01/2017)
6.	Shin, Kogyoku: 1 article (01/2017)
7.	Taguchi, Ryota: 1 article (01/2017)

Related Diseases

1.	Visceral Pain 01/01/2017 - "Here, we investigated the effects of E2508 on wrap restraint stress-induced defecation and visceral pain in rats. " 01/01/2017 - "Selective corticotropin-releasing factor 1 receptor antagonist E2508 reduces restraint stress-induced defecation and visceral pain in rat models." 01/01/2017 - "Oral pretreatment with E2508 dose-dependently decreased stool weights after 20min wrap restraint stress and significant effects were observed at doses of 30 and 100mg/kg. However, E2508 did not affect basal defecation at doses up to 100mg/kg. In contrast, alosetron, a 5-HT3 receptor antagonist, decreased both wrap restraint stress-induced and basal stool output at a dose of 0.1mg/kg. In a rat visceral pain model, subcutaneous injections of both E2508 (0.01 and 0.1mg/kg) and alosetron (0.001 and 0.01mg/kg) significantly decreased the number of abdominal muscle contractions induced by colonic distention, suggesting these drugs reduced visceral pain. "
2.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 01/01/2017 - "Together, these results demonstrate E2508 has the potential to be an effective therapy for the treatment of irritable bowel syndrome with a lower risk of adverse events such as constipation compared with the current clinically used 5-HT3 receptor antagonist."
3.	Constipation 01/01/2017 - "Together, these results demonstrate E2508 has the potential to be an effective therapy for the treatment of irritable bowel syndrome with a lower risk of adverse events such as constipation compared with the current clinically used 5-HT3 receptor antagonist."

Related Drugs and Biologics

1.	5-HT3 Serotonin Receptors (5 HT3 Receptor)
2.	Corticotropin-Releasing Hormone
3.	alosetron (Lotronex)

Related Therapies and Procedures

1.	Therapeutics
2.	Subcutaneous Injections